Despite significant advances in the treatment of people with HIV infection, professional practice gaps remain that contribute to continued morbidity and mortality. While clinical trials provide an evidence base regarding which ARV drugs and regimens are most likely to be effective for treating various patients, many HIV clinicians have not integrated them into their clinical practice. To address this problem, we have developed a case-based CME program that explores and analyzes current HIV treatment standards of care, including when to start, what to start in ARV-naive patients, and when to switch ARVs in virologically suppressed patients for the purpose of eliminating or avoiding toxicity, improving long-term patient health, or simplifying a regimen. Participants in this program will gain knowledge and skills that should lead to improved patient care.
This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HIV infection.
Upon completion of the program, participants should be able to:
Release Date: August 31, 2018
Expiration Date: August 31, 2019
Estimated time to complete each Module: 30 minutes per indivitual moduels, 3 hours for "Play All" option
Media: Web
Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of
Pennsylvania
Philadelphia, Pennsylvania
Wilbert Jordan, MD
Medical Director,
Charles Drew Medical Center
Los Angeles, California
Anthony Mills, MD
Southern California Men's Medical Group
Los Angeles, California
Paul Sax, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Renslow Sherer, MD
Professor
of Medicin
Section
of Infectious Diseases and Global Health
University
of Chicago
Chicago,
Illinois
|
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and ViralEd, Inc. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians. |
Module 1 (
Initiate Therapy to
Patients with HIV that Minimizes Side Effects and Supports Adherence):
The Annenberg Center for Health Sciences
at Eisenhower designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 2 (Identify and Remove
Barriers to Successful Communications with HIV-Positive Patients):
The Annenberg Center for Health Sciences
at Eisenhower designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 3 (Effectively Treat
HIV-Positive Patients and Co-morbid Conditions):
The Annenberg Center for Health Sciences
at Eisenhower designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 4 (Switching ART to
Reduce Side-Effects and/or Pill Burden):
The Annenberg Center for Health Sciences
at Eisenhower designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 5 (Provide Effective
Treatment for HIV-Positive Patients who are Failing ARV Therapy):
The Annenberg Center for Health Sciences
at Eisenhower designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 6 (Provide
Individualized HIV Care to Minority Patients that Supports Adherence to ARV
Therapy):
The Annenberg Center for Health Sciences
at Eisenhower designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Play All Option:
The Annenberg Center for Health Sciences
at Eisenhower designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The Annenberg Center for Health Sciences at Eisenhower is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Ian Frank, MD
•Consulting Fees: Gilead
•Contracted Research: ViiV/GlaxoSmithKline
Wilbert Jordan, MD:
•No real or apparent conflicts to disclose
Anthony Mills, MD
•Consulting Fees: Gilead, ViiV, Merck
•Fees for Non-CME/CE Services Received Directly from a Commercial Interest: Gilead
•Contracted Research: Gilead, ViiV, Merck
Paul Sax, MD:
•Consulting Fees: AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Janssen, Merck
•Contacted Research: NIH, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Merck
•Other (Editorial Boards): Medscape, UpToDate, Open Forum Infectious Diseases
Renslow Sherer, MD:
•Consulting fees: Gilead
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Amanda Glazar, PhD, CHCP have nothing to disclose.
Charles E. Willis, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower consults for Pfizer, Inc; Amanda Sewell, MBA, Manager of Continuing Education and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
There are no fees for participating and receiving CME credit for this activity. During the period, August 31, 2018 through August 31, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 13490. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This program requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable version of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player and Real Networks Real One Player.
This activity is supported by an independent educational grant from ViiV Healthcare
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and ViralEd, Inc., in collaboration with Postgraduate Institute for Medicine.
